Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

250 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Pharmacokinetics of single-agent axitinib across multiple solid tumor types.
Tortorici MA, Cohen EE, Pithavala YK, Garrett M, Ruiz-Garcia A, Kim S, Fruehauf JP. Tortorici MA, et al. Among authors: cohen ee. Cancer Chemother Pharmacol. 2014 Dec;74(6):1279-89. doi: 10.1007/s00280-014-2606-6. Epub 2014 Oct 22. Cancer Chemother Pharmacol. 2014. PMID: 25336084
Axitinib is an active treatment for all histologic subtypes of advanced thyroid cancer: results from a phase II study.
Cohen EE, Rosen LS, Vokes EE, Kies MS, Forastiere AA, Worden FP, Kane MA, Sherman E, Kim S, Bycott P, Tortorici M, Shalinsky DR, Liau KF, Cohen RB. Cohen EE, et al. Among authors: cohen rb. J Clin Oncol. 2008 Oct 10;26(29):4708-13. doi: 10.1200/JCO.2007.15.9566. Epub 2008 Jun 9. J Clin Oncol. 2008. PMID: 18541897 Free PMC article. Clinical Trial.
Diastolic blood pressure as a biomarker of axitinib efficacy in solid tumors.
Rini BI, Schiller JH, Fruehauf JP, Cohen EE, Tarazi JC, Rosbrook B, Bair AH, Ricart AD, Olszanski AJ, Letrent KJ, Kim S, Rixe O. Rini BI, et al. Among authors: cohen ee. Clin Cancer Res. 2011 Jun 1;17(11):3841-9. doi: 10.1158/1078-0432.CCR-10-2806. Epub 2011 Apr 29. Clin Cancer Res. 2011. PMID: 21531811
Treatment of advanced thyroid cancer with axitinib: Phase 2 study with pharmacokinetic/pharmacodynamic and quality-of-life assessments.
Locati LD, Licitra L, Agate L, Ou SH, Boucher A, Jarzab B, Qin S, Kane MA, Wirth LJ, Chen C, Kim S, Ingrosso A, Pithavala YK, Bycott P, Cohen EE. Locati LD, et al. Among authors: cohen ee. Cancer. 2014 Sep 1;120(17):2694-703. doi: 10.1002/cncr.28766. Epub 2014 May 20. Cancer. 2014. PMID: 24844950 Free article. Clinical Trial.
Sorafenib dose escalation is not uniformly associated with blood pressure elevations in normotensive patients with advanced malignancies.
Karovic S, Wen Y, Karrison TG, Bakris GL, Levine MR, House LK, Wu K, Thomeas V, Rudek MA, Wright JJ, Cohen EE, Fleming GF, Ratain MJ, Maitland ML. Karovic S, et al. Among authors: cohen ee. Clin Pharmacol Ther. 2014 Jul;96(1):27-35. doi: 10.1038/clpt.2014.63. Epub 2014 Mar 17. Clin Pharmacol Ther. 2014. PMID: 24637941 Free PMC article. Clinical Trial.
An open-label single-arm, phase II trial of zalutumumab, a human monoclonal anti-EGFR antibody, in patients with platinum-refractory squamous cell carcinoma of the head and neck.
Saloura V, Cohen EE, Licitra L, Billan S, Dinis J, Lisby S, Gauler TC. Saloura V, et al. Among authors: cohen ee. Cancer Chemother Pharmacol. 2014 Jun;73(6):1227-39. doi: 10.1007/s00280-014-2459-z. Epub 2014 Apr 9. Cancer Chemother Pharmacol. 2014. PMID: 24714973 Clinical Trial.
Immunotherapy of head and neck cancer: Emerging clinical trials from a National Cancer Institute Head and Neck Cancer Steering Committee Planning Meeting.
Bauman JE, Cohen E, Ferris RL, Adelstein DJ, Brizel DM, Ridge JA, O'Sullivan B, Burtness BA, Butterfield LH, Carson WE, Disis ML, Fox BA, Gajewski TF, Gillison ML, Hodge JW, Le QT, Raben D, Strome SE, Lynn J, Malik S. Bauman JE, et al. Cancer. 2017 Apr 1;123(7):1259-1271. doi: 10.1002/cncr.30449. Epub 2016 Dec 1. Cancer. 2017. PMID: 27906454 Free PMC article.
250 results